|
Pfizer to acquire Global Blood Therapeutics for $5.4 billion to enhance presence in rare hematology
|
08 August 2022 |
|
Pfizer and BioNTech advance COVID-19 vaccine strategy with study start of next-generation vaccine candidate based on enhanced spike protein design
|
27 July 2022 |
|
Pfizer and BioNTech complete submission to European Medicines Agency for Omicron BA.1 adapted bivalent vaccine candidate
|
19 July 2022 |
|
Pfizer and BioNTech announce new agreement with U.S. government to provide additional doses of COVID-19 vaccine
|
01 July 2022 |
|
Pfizer and BioNTech announce Omicron-adapted COVID-19 vaccine candidates demonstrate high immune response against Omicron
|
25 June 2022 |
|
Pfizer to invest $120 million to produce COVID-19 oral treatment in the U.S.
|
08 June 2022 |
|
Pfizer 'aunches 'An Accord for a Healthier World' to improve health equity for 1.2 billion people living in 45 lower-income countries
|
25 May 2022 |
|
Pfizer to acquire Biohaven Pharmaceuticals
|
10 May 2022 |
|
Pfizer shares top-line results from Phase 2/3 EPIC-PEP study of PAXLOVID™ for post-exposure prophylactic use
|
02 May 2022 |
|
Pfizer and Biohaven's VYDURA® (rimegepant) granted first ever marketing authorization by European Commission for both acute treatment of migraine and prophylaxis of episodic migraine
|
27 April 2022 |
|
Pfizer to acquire ReViral and its respiratory syncytial virus therapeutic candidates
|
07 April 2022 |
|
Pfizer to supply UNICEF up to 4 million treatment courses of novel COVID-19 oral treatment for low- and middle-income countries
|
22 March 2022 |
|
Pfizer and BioNTech aubmit for U.S. Emergency Use Authorization of an additional booster dose of their COVID-19 vaccine for older adults
|
17 March 2022 |
|
Pfizer updates company position in Russia
|
14 March 2022 |
|
Valneva and Pfizer report further positive Phase 2 data for Lyme disease vaccine candidate
|
04 February 2022 |
|
Pfizer receives CHMP positive opinion for novel COVID-19 oral treatment
|
01 February 2022 |
|
Pfizer and BioNTech initiate study to evaluate Omicron-based COVID-19 vaccine in adults 18 to 55 years of age
|
26 January 2022 |
|
Pfizer and BioNTech publish data from two laboratory studies on COVID-19 vaccine-induced antibodies ability to neutralize SARS-CoV-2 Omicron variant
|
24 January 2022 |
|
Pfizer shares in vitro efficacy of novel COVID-19 oral treatment against omicron variant
|
18 January 2022 |
|
Pfizer and BioNTech receive U.S. FDA Emergency Use Authorization of COVID-19 vaccine booster for individuals 12 years of age and older
|
04 January 2022 |